Lipids in Pulmonary Drug Delivery

- Lipid Nanotechnology - Current Scenario and Challenges of Lipid-Based Nanomedicines for Pulmonary Drug Delivery - Effect of Environment of the Respiratory Tract on Nanomedicine Drug Delivery - Aerodynamics and Deposition of Lipid-Based Nanocarriers in Lungs - Liposome as a Versatile Carrier for Pulmonary Drug Delivery - Advancements in Nano-Structured Lipid Carrier (NLCs) as Drug Delivery Vehicle in Lungs - Solid Lipid Nanoparticles: A Potential Drug Carrier in Pulmonary System - Insights and Applications of Nanoemulsions as a Drug Carrier in Lungs - Lipid-Based Drug Delivery for Lung Cancer - Exploring the State-of-Art of Lipid Nanomedicines for Obstructive Pulmonary Diseases - Lipid-Based Drug Delivery for Pulmonary Microbial Infections - Lipid-Based Drug Delivery for Systemic Effect Through Pulmonary Route of Administration - Biofate of Lipid-Based Nanomedicine After Pulmonary Administration - Surface Modification of Lipid-Based Drug Delivery for Lungs - Evaluation of Lipid-Based Formulation for Pulmonary Delivery - Physico-Chemical Stability of Lipid-Based Nanocarriers in Aerosol Formulation - Translation of Lipid-Based Formulation for Pulmonary Drug Delivery System: Clinical Status - Regulatory Aspects of Lipid-Based Nanomedicine for Pulmonary Applications - Lipid-Based Vaccines Against Viruses Including COVID-19 - Lipid-Based Nanocarriers in the Management of Cystic Fibrosis: A Pulmonary Complication - Pulmonary Drug Delivery of Lipid-Based Formulations via Nebulizers - Lipid-Based Peptide and Gene Delivery to Lungs